Reply to: "Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease"
- PMID: 33676949
- DOI: 10.1016/j.jhep.2021.02.030
Reply to: "Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease"
Keywords: NAFLD; cirrhosis; genetics; hepatocellular carcinoma; polygenic risk score.
Conflict of interest statement
Conflict of interest The authors declare that they have no conflict of interest relevant to the present study. LV has received speaking fees from MSD, Gilead, AlfaSigma and AbbVie, served as a consultant for Gilead, Pfizer, AstraZeneca, Novo Nordisk, Intercept, Diatech Pharmacogenetics and Ionis Pharmaceuticals, and received research grants from Gilead. SR has served as a consultant for AstraZeneca, Celgene, Sanofi, Amgen, Akcea Therapeutics, Camp4, Ambys, Medacorp, Novartis and Pfizer in the past 5 years, and received research grants from AstraZeneca, Sanofi and Amgen. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.J Hepatol. 2021 Apr;74(4):775-782. doi: 10.1016/j.jhep.2020.11.024. Epub 2020 Nov 25. J Hepatol. 2021. PMID: 33248170 Free PMC article.
-
Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease.J Hepatol. 2021 Jun;74(6):1493-1494. doi: 10.1016/j.jhep.2021.01.010. Epub 2021 Jan 18. J Hepatol. 2021. PMID: 33476746 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical